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Abstract
Multiple sclerosis (MS) is a chronic, progressive disorder of the central nervous system (CNS) that
affects more than two million people worldwide. Several animal models resemble MS pathology;
the most employed are experimental autoimmune encephalomyelitis (EAE) and toxin- and/or virus-
induced demyelination. In this review we will summarize our knowledge on the utility of different
animal models in MS research. Although animal models cannot replicate the complexity and heter-
ogeneity of the MS pathology, they have proved to be useful for the development of several drugs
approved for treatment of MS patients. This review focuses on EAE because it represents both
clinical and pathological features of MS. During the past decades, EAE has been effective in
illuminating various pathological processes that occur during MS, including inflammation, CNS pen-
etration, demyelination, axonopathy, and neuron loss mediated by immune cells.
K E YWORD S
EAE, ethidium bromide, glial cells, lysolecithin toxin and virus-induced demyelination, multiple
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1 | INTRODUCTION
Multiple sclerosis (MS) is a neuroinflammatory, demyelinating disease
that is characterized by accumulation of disability. Generally, it is
thought to be an autoimmune, T cell–mediated disease. However, the
etiology of MS is still unclear, although many environmental factors
and the interplay of multiple genes have been proposed to play a role
in disease occurrence. MS is most often diagnosed between ages 20
and 40 and is more common in females than in males (now almost 3:1).
Three courses of the disease are recognized: relapsing–remitting MS,
primary progressive MS, and secondary progressive MS. The relapsing–
remitting course initially affects most MS patients; it is most often
succeeded by a secondary progressive disease course, which is charac-
terized by a buildup of neurological deficits. The primary progressive
course affects 10% to 15% of patients and is described as a progressive
disease without relapses.
The two main pathological features of MS are inflammation and
demyelination. In addition, activation of astrocytes and microglia, apo-
ptosis of oligodendrocytes, and axonal loss (Bjartmar, Wujek, & Trapp,
2003; Kornek et al., 2000) are found within the affected central nerv-
ous system (CNS). A multifaceted relationship between different cell
types that lead to demyelination and remyelination in the CNS during
MS has been uncovered using animal models. Although the established
animal models have their advantages/disadvantages, no model fully
replicates the stages of MS. There are several established experimental
demyelination models that, to some extent, reflect the heterogeneity
of MS and are therefore seen as suitable to study MS pathogenesis.
These models include immune-mediated, virus-induced, and toxin-
induced models. Experimental autoimmune encephalitis (EAE) is, by far,
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the most exploited model for studying various aspects of autoimmunity
in MS pathology. Virus-induced demyelination models support the
hypothesis that some environmental factors, such as viral infections,
are involved in MS and may be a trigger of the disease. Toxin-induced
demyelination models are means in the evaluation of the demyelin-
ation/remyelination process in the relative absence of immune cells,
even though these ways of damaging the myelin do not resemble fea-
tures of the demyelination seen in MS.
Despite the limitations, a wide variety of phenomena relevant for
understanding pathological events in MS and management of different
therapies can be learned from animal models. In this review, we discuss
several well-established experimental demyelination models that are
available to study MS pathogenesis, with a special focus on EAE. We
will describe the animals selected to induce EAE and address some of
their genotypic and phenotypic features. The role and involvement of
glial cells will also be reported. The recent advances in creating next-
generation models for MS will be reviewed.
2 | TOXIN-INDUCED
DEMYELINATION MODELS
There are several agents known to generate demyelination foci, using
direct injections of gliotoxins in the white matter, such as ethidium bro-
mide (EtBr) and lysolecithin, or systemically administered toxins, such
as cuprizone (Woodruff & Franklin, 1999). These models are indispen-
sable for studying remyelination processes in animals. Further, these
models ensure good reproducibility and well-defined anatomical loca-
tion of the demyelination area.
Calcium ionophore, antibodies against galactocerebroside,
6-aminonicotinamide, and diphtheria toxin can also be used as demyeli-
nating agents; however, these approaches are not considered to be suita-
ble models for gaining insights into the remyelination processes. Another
drawback of these models lies in the absence of the immune activity.
2.1 | Ethidium bromide
EtBr, as an intercalating agent, is toxic for all cells with nuclei and can
be used to create a focal demyelination lesion. It is assumed that EtBr
intercalates with both chromosomal and mtDNA, but influences
only mtDNA transcription (Kuypers, James, Enzmann, Magnuson, &
Whittemore, 2013). Accordingly, EtBr injection preferentially compro-
mises mtDNA transcription in glial cells rather than neurons and endo-
thelial cells. To achieve demyelination, stereotactic injection of EtBr is
delivered into specific white matter tracts, such as the thoracolumbar
dorsal funiculus of the spinal cord or in the caudal cerebellar peduncle.
Similarly, optic neuritis is generated upon EtBr injection into the subar-
achnoid space (Merrill, 2009).The EtBr model also has been carried out
extensively in the rat as a demyelinating model to assess endogenous
remyelination (Blakemore & Franklin, 2008); recently, it was used to
identify white matter tracts responsible for locomotor function in mice
(Kuypers et al., 2013; Salem, Assaf, Ismail, Khadrawy, & Samy, 2016).
The hallmark of EtBr delivery to white matter, and thus induced lesions,
is astrocyte and oligodendrocyte loss, while axons persist to be
FIGURE 1 Schematic representation of toxin-induced models of
demyelination. Ethidium bromide (EtBr) induced astrocyte, oligo-
dendrocyte, and OPC apoptosis within the first week (W1) after
injection. Remyelination starts 6 weeks (W6) after EtBr delivery
into the white matter of the CNS. In contrast, lysophosphatidyl-
choline (LPC) does not induce death of oligodendrocytes, OPC,
and astrocytes, and remyelination is faster, starting 3 weeks (W3)
after LPC injection. Cuprizone intoxication leads to apoptosis of
oligodendrocytes. Activation of microglia starts 2 weeks (W2) after
treatment with cuprizone and gradually decreases with the remye-
lination process. Astrocyte activation persists throughout the dis-
ease. Spontaneous remyelination occurs after cessation of
cuprizone intoxication [Color figure can be viewed at wileyonlineli-
brary.com]
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unaffected (Blakemore, 2005). Apoptosis of oligodendrocytes occurs
3 days after the EtBr injection; afterwards, the remyelination process
starts (Figure 1) (Guazzo, 2005). However, regardless of the absence of
oligodendrocytes in demyelination foci, Schwann cells migrate to the
lesion epicenter and remyelinate, as confirmed in both rats and cats after
EtBr delivery into the white matter of the spinal cord (Blakemore, 1982;
Woodruff & Franklin, 1999). Studies regarding the EtBr model also
report transient or persistent inflammatory response, probably because
astrocyte death compromises the blood-brain barrier (BBB), leading to
the infiltration of peripheral inflammatory cells (Kuypers et al., 2013).
However, lymphocyte infiltration observed after a single EtBr injection
was also proposed to be a consequence of the general immune activity.
The advantage of this model is that one can predict a demyelin-
ation site and determine the size of the lesion that is concentration
dependent. Age is a limiting factor with regard to remyelination after
EtBr injection, meaning that spontaneous myelin recovery decreases
with animal age (Ibanez et al., 2004). An immunological disorder that
shares some resemblance to MS, Devic’s disease, is also characterized
by massive Schwann cell–mediated remyelination, as observed in EtBr-
induced lesions (Ikota, Iwasaki, Kawarai, & Nakazato, 2010). In addition,
EtBr injection into the hippocampus may be employed as a model to
study cognition and alterations that occur in the gray matter (Goudarz-
vand et al., 2016), a feature that also occurs in MS.
2.2 | Lysolecithin
The toxic effect of another agent that is able to produce demyelination,
lysophosphatidylcholine (lysolecithin), was first described by Hall
(1972). With detergent-like agent activity, lysolecithin is able to solubi-
lize membranes and is considered to be selective for myelin-producing
cells. Therefore, lysolecithin targets the myelin, leaving other cellular
components relatively unaffected, thus allowing for the recruitment of
T and B cells, as well as microglia/macrophage activation at the lesion
site, which have a role in clearing myelin debris and in promotion of
trophic factors (Procaccini, De Rosa, Pucino, Formisano, & Matarese,
2015). Lysolecithin injection increases phospholipase A2 activity, which
is restricted to activated macrophages (Trotter & Smith, 1986). Phos-
pholipase A2 further degrades membrane phosphatidylcholines (Welt-
zien, 1979). Usually, 1% lysolecithin solution is injected into the dorsal
funiculus of the spinal cord, caudal cerebellar peduncle (Woodruff &
Franklin, 1999), or corpus callosum (Keough, Jensen, & Yong, 2015).
Following lysolecithin injection, the formed lesion changes over the
next few weeks and is capable of remyelinating completely, starting at
the end of the first week after the injection (Blakemore & Franklin,
2008). The remyelination process in this model is faster compared with
other toxin-induced demyelination models, mainly because oligoden-
drocyte progenitor cells (OPCs) are not affected (Blakemore & Franklin,
2008). Demyelinating axons are remyelinated mainly by oligodendro-
cytes. However, if the lesion is larger in size, Schwann cells also take
part in the remyelination process. As in the EtBr model, remyelination
occurs faster in young animals of different species (Shields, Gilson, Bla-
kemore, & Franklin, 1999). Remyelination begins only after the myelin
debris is removed—that is, about 7 days post lysolecithin injection in
the spinal cord of mice or young adult rats, when pale myelin sheaths
begin to appear. When the lysolecithin injection is delivered into the
caudal cerebellar peduncle, remyelination is rather slow compared with
spinal cord injection. In these cases, remyelination starts 3 weeks after
the injection, and compact myelin appears 6 weeks post demyelination
(Woodruff & Franklin, 1999). Lysolecithin treatment, in contrast to
EtBr, does not induce a loss of astrocytes, OPCs, or macrophages, thus
facilitating faster remyelination (Figure 1). The recurrent pattern of pri-
mary demyelination that can be controlled in a spatiotemporal manner
is an advantage of this model of demyelination. Lysolecithin-induced
demyelination can also be performed in nonhuman primates. Namely,
demyelination/remyelination processes were evaluated in adult Macaca
fascicularis upon lysolecithin injection in the optic nerve or spinal cord.
The remyelination occurs in the spinal cord, while it fails in the optic
nerve (Lachapelle et al., 2005).
Therefore, lysolecithin proves to be a useful method to study de-
and remyelination in the CNS. The disadvantage of the lysolecithin
model of demyelination lies in the absence of the immune response
that is normally observed during MS.
2.3 | Other toxins
The toxins that are able to induce demyelination, but are not widely in
use, are described below.
The injection of the calcium ionophore, ionomycin, into the dorsal
column of the spinal cord induces myelin vesiculation that progresses
and forms confluent, large demyelination foci leading to axon degener-
ation in a dose-dependent manner (Smith & Hall, 1988, 1994). This
type of lesion created by ionomycin injection resembles the lesion seen
in the lysolecithin model of demyelination (Smith & Hall, 1988).
An antimetabolite of niacin and a well-known gliotoxin,
6-aminonicotinamide, is used to induce glial degeneration, especially in
the gray matter of adult rats (Horita, Ishii, & Izumiyama, 1981; Schneider
& Cervos-Navarro, 1974). Delivery of 6-aminonicotinamide into the spi-
nal cords of rats induces formation of demyelination foci, while astro-
cytes and oligodendrocytes undergo degeneration. The remyelination
process depends on Schwann cells, except for a few axons that
are myelinated by oligodendrocytes (Blakemore, 1975). In cats,
6-aminonicotinamide injection into the spinal cord causes massive death
of axons and glial cells. Surviving demyelinated axons are remyelinated
by Schwann cells. However, because of extensive axonal damage, this
approach is not considered to be a suitable model system for the study
of cellular relationships during remyelination (Blakemore, 1978).
It was postulated that diphtheria toxin might produce a useful
model for studying central demyelination (Harrison, McDonald, &
Ochoa, 1972). After diphtheria toxin exposure, axons in demyelination
foci show extremely thin myelin sheets, which is the main characteristic
of this model. Later, it was seen that a small dose of diphtheria toxin
induces peripheral demyelination in the presence of axonal degenera-
tion (Baba, Gilliatt, Harding, & Reiners, 1984). The use of diphtheria
toxin with regard to cell depletion was shown, where anatomically tar-
geted oligodendrocyte death can also be induced by recombination in
transgenic mice carrying a floxed diphtheria toxin (fragment A)
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(Brockschnieder et al., 2004; Brockschnieder, Pechmann, Sonnenberg-
Riethmacher, & Riethmacher, 2006).
2.4 | Antibody-mediated demyelination
Galactocerebrosides are greatly enriched in myelin membranes of the
CNS; they are also markers of immature oligodendrocytes (Dousset
et al., 1995). Antibodies to these glycolipids were used as a specific
cell-surface antigen to identify oligodendrocytes in cell culture (Raff
et al., 1978). The well-established animal model of human demyelin-
ation neuritis, experimental allergic neuritis, may be induced by inocula-
tion with galactocerebroside antibodies. No changes occur in the CNS,
but several small perivascular areas of demyelination are found in the
dorsal roots of the spinal cord and dorsal root ganglia (Saida, Saida, Sil-
berberg, & Brown, 1981). However, inoculation of these antibodies
with complete Freund’s adjuvant (CFA) failed to induce demyelination
in guinea pigs (Khang, Chi, & Lee, 1988). Further, delivery of these anti-
bodies into the spinal cord induces demyelination, and this approach
can preserve oligodendrocytes that are able to start the remyelination
process (Keirstead & Blakemore, 1997). In addition, a similar pattern of
demyelination occurs after injection of these glycolipids into the caudal
cerebellar peduncle, forming demyelination foci that are remyelinated
by oligodendrocytes (Woodruff & Franklin, 1999). In these models, the
axons are more preserved from degeneration compared with the lyso-
lecithin model. Therefore, galactocerebroside antibodies may be
employed as an approach to evaluate axonal cytoskeleton changes
upon demyelination. It is likely that demyelination is induced through
the myelin-lysis and oligodendrocyte-lysis process because it was pre-
viously shown that these antibodies are toxic to myelin and oligoden-
drocytes in vitro (Raine, Johnson, Marcus, Suzuki, & Bornstein, 1981).
2.5 | Cuprizone
Cuprizone (oxalic acid bis [cyclohexylidene hydrazide]) is a well-known
copper-chelating agent that is known to be toxic to myelin sheet.
Cuprizone-induced demyelination is a straightforward model used to
investigate brain-intrinsic inflammatory responses, together with demy-
elination/remyelination processes. The hallmark of the lesions that
cuprizone elicits is oligodendrocyte dysfunction. This model was re-
garded as a typical white matter demyelination model; however, recent
studies confirm that gray matter is also afflicted (Goldberg, Clarner,
Beyer, & Kipp, 2015; Khodanovich et al., 2017).
The first described experiments using cuprizone as a toxic
compound were conducted by Carlton, who reported that cuprizone
intoxication forms small lesions throughout the brain, followed by
hydrocephalus, spongy demyelination, and astrogliosis (Carlton, 1967).
Later, cuprizone intoxication was introduced as an in vivo model for
chemically induced demyelination that can be controlled in a spatiotem-
poral manner (Ludwin, 1978). The first observation that cuprizone
causes oligodendrocyte death with consequent microgliosis was pre-
sented by Blakemore (1972). He also noticed remyelinating axons in
some areas of the brain. Since then, it has been reported that cuprizone
is a suitable model for studying demyelination events during MS
because it provides a highly reproducible system for exploring oligoden-
drocyte apoptosis and secondary demyelination (Matsushima & Morell,
2001). During cuprizone-induced demyelination, the apoptosis of oligo-
dendrocytes occurs 3 days after cuprizone exposure (Hesse et al.,
2010; Mason et al., 2004). Oligodendrocytes exhibit pycnotic nuclei,
with enlarged mitochondria and big vacuoles, suggesting that oligoden-
drocytes are dying primarily because of caspase-3-dependent apoptosis
(Kipp, Nyamoya, Hochstrasser, & Amor, 2017). Even though the precise
mechanism of oligodendrocyte death is not fully understood, it is
assumed that cuprizone causes dysfunction of mitochondrial enzymes
with subsequent oxidative stress, leading to metabolic stress in oligo-
dendrocytes (Miljković & Spasojević, 2013). Typically, the apoptosis of
oligodendrocytes appears after 2 days, as a consequence of cuprizone
intoxication, before demyelination is obvious (Buschmann et al., 2012).
The demyelination is usually evident 3 weeks after the start of cupri-
zone administration and correlates with immense microgliosis, astroglio-
sis, and axon damage (Doan et al., 2013; Kipp et al., 2017). Six weeks
after cuprizone ingestion, demyelination occurs globally, but it is most
prominent in the corpus callosum and posterior cerebellar peduncles
and is referred to as “acute demyelination.” Acute demyelination is fol-
lowed by spontaneous remyelination, when a cuprizone diet is replaced
by normal chow. The remyelination process is dependent on OPC mat-
uration, and the reappearance of myelin in white matter is more
obvious than in gray matter, where proliferation and differentiation of
OPC is prolonged in cuprizone-induced demyelination (Baxi et al.,
2017). On the contrary, prolonged cuprizone intoxication (more than 12
weeks) results in a constrained spontaneous remyelination process:
“chronic demyelination.” During chronic stages of the disease, apoptosis
of oligodendrocytes occurs in a caspase-3–independent manner (Gudi,
Gingele, Skripuletz, & Stangel, 2014). Systemic application of cuprizone
generates demyelination in the corpus callosum; however, a loss of
myelin is also observed in the cortex, hippocampus, and cerebellum
(Baxi et al., 2017; Kipp, Clarner, Dang, Copray, & Beyer, 2009).
The role of microglia in this animal model is still under debate. Acti-
vation of microglia precedes demyelination, starting after 2 weeks of
intoxication. The number of microglia gradually increases over the fol-
lowing weeks and decreases subsequently until complete demyelin-
ation (Skripuletz, Gudi, Hackstette, & Stangel, 2011). However, the
presence of activated microglia persists during the chronic phase of the
disease (Lindner, Fokuhl, Linsmeier, Trebst, & Stangel, 2009; Mason
et al., 2004). It is well known that microglial cells are involved in phago-
cytosis of disrupted myelin sheets. Also, microglial production of proin-
flammatory mediators increases because of cuprizone-induced
oligodendrocyte death. On the other hand, microglia may take part in
promoting remyelination (Praet, Guglielmetti, Berneman, Van der Lin-
den, & Ponsaerts, 2014). Accordingly, it was observed that massive
accumulation of OPCs occurs between 3 and 5 weeks of intoxication,
when microglial activation is most apparent (Gudi et al., 2014). Astro-
cytes also increase in size and number (Gudi et al., 2014; Hiremath
et al., 1998) and continue to be activated during the chronic phase of
disease (Kipp et al., 2011; Lindner et al., 2009). The activation status at
this stage of the disease seems to be higher compared with astrocytes
observed at the acute cuprizone-induced demyelination (Gudi et al.,
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2014; Hiremath et al., 1998; Kipp et al., 2011; Ludwin 1978). It appears
that astrocytes have a role in the remyelination process in this model
because they continue to be activated even upon cessation of cupri-
zone intoxication (Skripuletz et al., 2013) (Figure 1).
Consequences of cuprizone-induced demyelination on functional
deficits in behavioral and cognitive manner were not evaluated com-
prehensively. Thus far, decreased motor coordination of mice in the
Rotarod test, impaired social behavior and sensorimotor function, as
well as reduced anxiety have been described, although some of these
deficits are withdrawn upon remyelination (Franco-Pons, Torrente,
Colomina, & Vilella, 2007; Hibbits, Pannu, Wu, & Armstrong, 2009).
Cuprizone intoxication induces a variable degree of demyelination
that depends on the strain, age, and gender of animals as well as the
duration of exposure and dosage of this toxic agent. Indeed, it was
reported that when exposed to cuprizone, Swiss mice, BALB/c mice,
and Swiss Jim Lambert (SJL) mice show demyelination, but delayed or
incomplete (Ludwin, 1978; Skripuletz et al., 2008; Taylor, Gilmore, &
Matsushima, 2009). Cuprizone is widely used in C57BL/6 mice, which
has led to the development of a highly reproducible model of investigat-
ing demyelination/remyelination (Praet et al., 2014). Unlike mice, it was
reported that Wistar rats, guinea pigs, and Syrian and Chinese hamsters
do not develop areas of demyelination in the spinal cord upon cupri-
zone treatment (Love, 1988). However, more recent studies imply that
a higher dose of cuprizone can induce demyelination in the cortex and
subcortical areas in Wistar rats (Adamo et al., 2006; Basoglu, Boylu, &
Kose, 2013; Silvestroff, Bartucci, Pasquini, & Franco, 2012), while in
CD1 mice demyelination was not seen until 7 weeks after cuprizone
administration (Yu et al., 2017). It has been documented that female
SJL mice are partly resistant to demyelination and depletion of oligo-
dendrocytes (Taylor et al., 2009). On the contrary, cuprizone adminis-
tration induces similar demyelination in female and male C57BL/6 mice,
with estrous cycle disruption in females (Taylor, Gilmore, Ting, & Mat-
sushima, 2010). Therefore, use of the cuprizone model in male C57BL/
6 mice is recommended (Kipp et al., 2009) because of the involvement
of female hormones, which are known to be able to postpone demye-
lination and prompt remyelination. It was reported that the degree and
pattern of demyelination does not depend on the age of the mice (Shen
et al., 2008). However, oligodendrocyte turnover and recruitment of oli-
godendrocytes progenitor cells to the area of demyelination (Doucette,
Jiao, & Nazarali, 2010), together with constant decreases in spontane-
ous remyelination, occurred in the old mice. The observed decline in
remyelination capacity is probably due to differences in epigenetic and
transcriptional control in older animals (Shen et al., 2008).
Recently, cuprizone was used in combination with actively induced
EAE, resulting in inflammatory forebrain lesions (Ruther et al., 2017;
Scheld et al., 2016). Therefore, this model may be an extremely valua-
ble tool in MS research in the future.
In summary, the simplicity of the model, together with high reliabil-
ity and reproducibility, makes it ideal for inducing and examining demy-
elination/remyelination processes (Matsushima & Morell, 2001). As in
other toxin-induced demyelination, the drawback of this model is the
lack of immune system involvement, which is an important component
of MS pathogenesis (Table 1).
3 | THEILER ’S MURINE
ENCEPHALOMYELITIS VIRUS
Considering the relevance of infectious factors contributing to MS,
viruses have been thought to play a role in the initiation and progression
of this disease (Bjelobaba, Savic, & Lavrnja, 2017). Consequently, suitable
animal models that involve virus-induced demyelination are generated by
Theiler’s virus, canine distemper virus, and mouse hepatitis virus (Lass-
mann & Bradl, 2017). The best-characterized virus-induced demyelin-
ation model is Theiler’s murine encephalomyelitis virus (TMEV). TMEV
infection of mice represents a neurotropic viral infection model of MS
and has been widely used (Libbey & Fujinami, 2003). It was discovered
by Max Theiler, who isolated TMEV from the CNS of spontaneously par-
alyzed mice (Theiler, 1934). TMEV is a nonenveloped, positive-stranded
RNA virus that belongs to the Cardiovirus genus from the Picornaviridae
family. TMEV is divided into two subgroups based on the ability to cause
demyelination in the CNS of susceptible animals. A highly virulent GDVII
leads to deadly encephalomyelitis in mice subjected to the virus. Specifi-
cally, neurons are the main target of GDVII virus infection. Affected neu-
rons exert fragmentation of the nucleus and chromatin condensation
(Tsunoda, Kurtz, & Fujinami, 1997) especially in the gray matter of the
cerebral cortex, hippocampus, and spinal cord. Although activated micro-
glia are present in the CNS, there is a lack of intense inflammatory reac-
tion. The other group, referred as Theiler’s original subgroup, consists of
Daniels and BeAn 8386 viral strains that are characterized by low viru-
lence and consequently fail to induce severe encephalitis (Daniels, Pap-
penheimer, & Richardson, 1952), while persistent infection occurs in the
CNS (Fuller, Olson, Howard, Croxford, & Miller, 2004; Tsunoda, Tanaka,
Taniguchi, & Fujinami, 2009).
The clinical outcome of infected animals depends both on the virus
and mouse strains. Accordingly, it was suggested that the SJL/J, DBA/
1 and 2, SWR, PL/J, and NZW mouse strains are highly susceptible,
C3H, CBA, AKR, and C57BR have intermediate susceptibility, and
BALB/c, C57BL/6J, C57BL/10, and C57/L are resistant to intracerebral
inoculation of TMEV (Dal Canto & Lipton, 1975; Dal Canto, Melvold, &
Kim, 1995; Lipton, 1975). However, the C57BL/6J strain of mice devel-
ops the early acute disease, together with faster and stronger immune
reaction, which is assumed to be crucial for complete clearing of the
virus and resistance to demyelination (Getts, Richards, & Miller, 2010;
Oleszak, Chang, Friedman, Katsetos, & Platsoucas, 2004). The compari-
son between the C57BL/6J and SLJ/J strains of mice in inducing
TMEV is discussed in detail elsewhere (DePaula-Silva, Hanak, Libbey, &
Fujinami, 2017). Generally, TMEV infection of susceptible strains of
mice results in the CNS disease, which comprises an early acute phase
of the disease and a late chronic demyelinating disease that starts 30
to 40 days after primary infection (Lassmann & Bradl, 2017; Mecha,
Carrillo-Salinas, Mestre, Feliu, & Guaza, 2013; Oleszak et al., 2004).
The early acute phase appears 3 to 12 days after infection in sus-
ceptible animals and is characterized by intense and multifocal inflam-
mation within the gray matter of the brain, rapid virus replication in
neurons, and neuronal apoptosis (Tsunoda & Fujinami, 2010). Extensive
inflammation consisting of virus-specific CD41 and CD81 T cells, mac-
rophages, and B cells (Tsunoda, Kuang, & Fujinami, 2002) occurs in the
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subcortical gray matter, the hippocampus, and the basal ganglia
(Johnson, Jin, Pirko, & Johnson, 2014; Pachner, 2011). Inflammation in
the spinal cord is not pronounced and is localized in the anterior horns
of the gray matter. During the early acute phase of TMEV infection,
the white matter of the spinal cord remains unaffected (Oleszak et al.,
2004). Also, it was postulated that during the acute phase, axonal dam-
age precedes demyelination; this inside-out model of demyelination is
a feature that was also observed during the chronic phase of disease
(Sato, Tanaka, Hasanovic, & Tsunoda, 2011). It has been proposed that
the axonal damage provokes the immune system to recruit proinflam-
matory mediators that generate the loss of myelin (Figure 2).
The chronic phase, which usually appears at about 30 days post
infection, is outlined by an inflammatory demyelination, together with
functional deficits, such as ataxia and spastic paralysis (Miller et al.,
1997; Procaccini et al., 2015). The pathological features at the onset of
the chronic phase include massive inflammation of the white matter
comprising primarily T cells and monocytes/macrophages, together
with microglial proliferation predominantly in the brain stem and thala-
mus, and perivascular inflammation in the spinal cord white matter
(Procaccini et al., 2015). During this phase of the disease, the highest
level of viral antigens has been demonstrated in astrocytes, microglia/
macrophages, and oligodendrocytes, but not in neurons. Histologically,
demyelination is characterized by an obvious loss of myelin and vacuo-
lization of the white matter, together with the appearance of phago-
cytic macrophages inside the lesions. Later, during the progressive
stages of the chronic phase of disease, within the areas of demyelin-
ation, axonal swellings can be found (McGavern, Murray, & Rodriguez,
1999; McGavern et al., 2000). Further, the observed secondary auto-
immune reactivity in the chronic phase of the disease does not appear
to be due to T cell–specific molecular mimicry, due to the epitope
spreading, where autoreactive T cells are triggered by constant release
of endogenous epitopes of myelin (Miller et al., 1997).
The similarities between this model and MS can be seen, although
the relapses are lacking in TMEV. Also, viral infections are linked to the
initiation and progression of MS (Bjelobaba, Savic, & Lavrnja, 2016),
and the autoimmune response upon TMEV infection that leads to axo-
nal damage shows a resemblance to MS. The pitfall of this model is
that experiments are time-consuming, and demyelination and remyeli-
nation occur simultaneously (Table 1).
4 | EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS
EAE is one of the most studied animal models of MS and imitates vari-
ous histopathological features and immunological facets of MS. There
are different types of EAE, each displaying some aspects of MS
(Table 1).
Therefore, it was suggested that EAE is a useful model of MS, if
used wisely (Baker & Amor, 2014). A detailed critical evaluation of EAE
as an MS model has been reviewed elsewhere (Baker, Gerritsen, Rundle,
& Amor, 2011; Behan & Chaudhuri, 2014). Generally, besides transgenic
mice that can spontaneously develop the disease, all animal strains used
in EAE models have to be immunized with self-antigen to develop the
disease (Croxford, Kurschus, & Waisman, 2011). As a consequence,
depending on animal strain, age, and gender, an acute and/or chronic–
relapsing inflammatory demyelinating autoimmune disease is acquired.
EAE can be induced through two different approaches: active immuniza-
tion with myelin peptides, or passively or adoptively transferred encepha-
litogenic T cells (Stromnes & Goverman, 2006a, 2006b).
4.1 | Active EAE
In actively induced EAE, susceptible strains of rodents (e.g., mice, rats,
guinea pigs) or nonhuman primates are subcutaneously immunized
FIGURE 2 Schematic overview of virus-induced demyelination and EAE model. TMEV infection induces axonal damage that precedes demyelination;
this inside-out model of demyelination is a feature that was also observed during the chronic phase of disease. Axonal damage aggravates immune cells
to recruit proinflammatory mediators to generate demyelination. During EAE, a variety of cells including dendritic cells, Th1, Th2, and Th17 break the
blood-brain barrier and enter the CNS. Resident glial cells become activated and promote demyelination with subsequent axonal damage (outside-in
model of demyelination) [Color figure can be viewed at wileyonlinelibrary.com]
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with a myelin-related antigen or peptide emulsified in CFA, a mineral
oil–based adjuvant supplemented with heat-inactivated mycobacteria
(Linker & Lee, 2009). The ratio of antigen and adjuvant is of crucial
importance for the EAE development. CFA is the most frequently used
adjuvant for EAE induction. While CFA promotes Th1 immune
response, an adjuvant lacking Mycobacterium tuberculosis (denoted as
incomplete Freund’s adjuvant [IFA]) induces a Th2-dominated
response. In addition to enhancing the peripheral immune response, an
advantage of CFA is that it increases BBB permeability, without
obvious activation of microglia and astrocytes (Rabchevsky, Degos, &
Dreyfus, 1999). The main disadvantage of Freund’s adjuvant is that it
can cause granulomas at the inoculation site and lesions.
To generate a disease, mice require additional injections of pertus-
sis toxin given on the day of immunization and 48hr after (Stromnes &
Goverman, 2006a). Pertussis toxin is a significant virulence factor of
Bordetella pertussis, and the mechanisms of enabling EAE induction by
pertussis toxin are complex. Although the precise effect of pertussis
toxin in EAE is unknown, it is thought to facilitate immune cell entry to
the CNS, as well as to promote proliferation and cytokine production
by T cells and break T cell tolerance (Waldner, Collins, & Kuchroo,
2000).
Immunization leads to the priming of myelin-specific T cells in the
secondary lymphoid organs. Activated T cells undergo maturation and
clonal expansion, thus forming a large pool of myelin-specific CD41 T
cells in the periphery. Later, they differentiate into effector cells and
become able to egress the secondary lymphoid organs through the
efferent lymphatic vessels and to pass into the blood circulation. The
entry of those cells to the CNS is accomplished upon an expression of
adhesion molecules, cytokines, and chemokines, together with their
receptors. All of this leads to disintegration of BBB (Engelhardt, 2006).
In the perivascular space or within CNS, effector T cells become reacti-
vated after they recognize antigens on antigen-presenting cells, such as
microglia/macrophages and/or astrocytes, which amplify inflammatory
response through continuous activation of those cells and constant
recruitment of other cells. These events are followed by secretion of
proinflammatory mediators attracting huge numbers of effector T cells
and mononuclear cells in the CNS, resulting in tissue damage and
demyelination (Figure 2) (McQualter & Bernard, 2007). Functional defi-
cit, such as tail and hind limb paralysis, occurs. T-regulatory cells (Tregs)
are also recruited in the CNS to regulate the immune response. During
the later stages of the disease, the higher number of Tregs leads to
EAE resolution (Kohm, Carpentier, Anger, & Miller, 2002). Furthermore,
it has been reported that high levels of cytokines, such as IFN-g, as
well as NO, may have a regulatory role by suppressing T cell responses
in the later stages of EAE disease (Arellano, Ottum, Reyes, Burgos, &
Naves, 2015).
4.2 | Passive EAE
Another way to induce EAE is accomplished with the adoptive transfer
by inoculating naïve syngeneic mice with activated, myelin antigen–
specific T cells, denominated as “passive EAE” (Racke, 2001). The first
verification that injection of lymph node cells from previously
sensitized rats into naïve rats may develop EAE was performed by
Paterson (1960). Twenty years later, the protocol for expansion of
antigen-specific T cells was established, and passive EAE with myelin
basic protein (MBP)-specific T cells was induced (Ben-Nun, Wekerle, &
Cohen, 1981).
Passive EAE proves to be valuable in evaluating the central role of
CD41 T cells during the disease. This model is also useful for studying
the effector phase of the disease in the absence of adjuvant. EAE
develops faster and more homogeneously, permitting the study of the
effector phase independently from the induction phase, which has
questionable relevance to MS (Wekerle, Kojima, Lannes-Vieira, Lass-
mann, & Linington, 1994). It is possible to manipulate the T cells in
vitro with a variety of inflammatory molecules prior to transfer, which
allows studying the influence of different subtypes of T cells involved
in the disease. Passive EAE can also be used to look at the migration
of T cells into the CNS more closely (McCarthy, Richards, & Miller,
2012). This model was important for finding proper anti-inflammatory
therapies (Gold, Linington, & Lassmann, 2006). The disadvantage of
passive EAE is that the myelin antigen–specific T cells transferred to
donor animals may not have the encephalitogenic capacity in vivo,
meaning that adoptive transfer of T cells may be unable to induce the
loss of myelin.
4.3 | Histopathology of EAE
Regardless of the animal used to induce EAE, the ongoing disease is
generally associated with encephalitogenic lymphocyte–mediated
demyelination. The initial period of EAE is characterized by perivascular
infiltration seen in the white matter of the CNS. During EAE, the
inflammatory response is accompanied by activation of microglia and
astrocytes, demyelination, and axonal loss, mainly seen at the peak of
the disease. The degree of damaged tissue correlates with the func-
tional deficit seen after the onset of EAE. The most pronounced
changes are observed in the spinal cord, while only sparse inflammation
is seen in the brain (Schmitt, Strazielle, & Ghersi-Egea, 2012). It is of
importance to note that the disease phenotype and histopathological
changes in the CNS vary, depending on the species and strain of ani-
mals used.
Microglia cells are a component of the innate immune system in
the CNS, and they serve to defend it from signs of danger and promote
repair. Microglia cells are involved in the progression of MS/EAE, since
they may serve as antigen-presenting cells to encephalitogenic T cells
in the CNS. Resting microglia gradually change their phenotype in
response to inflammation and demyelination and start to resemble clas-
sical activated macrophages (Kreutzberg, 1996). Macrophages from the
periphery are also found to promote EAE disease (Trifunovic et al.,
2015). These two populations of cells are functionally distinct; how-
ever, it is postulated that both macrophages and microglia have a role
in EAE pathogenesis (Duffy, Lees, & Moalem-Taylor, 2014). Upon acti-
vation, microglia dynamically rearrange a plethora of surface adhesion
molecules and receptors. Furthermore, cellular rearrangement of the
microglia cytoskeleton is observed subsequent to inflammation (Bozic,
Savic, Jovanovic, et al., 2015; Bozic, Savic, Laketa, et al., 2015). In
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addition, activated microglia have the ability to clear the damaged tis-
sue by phagocytosis (Sierra, Abiega, Shahraz, & Neumann, 2013), a fea-
ture needed for proper remyelination (Lampron et al., 2015). Activated
microglia display a proinflammatory phenotype that leads to a “vicious
cycle of inflammation” (Kettenmann, Hanisch, Noda, & Verkhratsky,
2011), which is characterized by production of potentially neurotoxic
substances, such as proinflammatory cytokines and oxygen/nitrogen
radicals (Bozic, Savic, Stevanovic, et al., 2015; Hanisch, 2013). Acti-
vated microglia may induce reactive astrocytes to be neurotoxic (Lidde-
low et al., 2017). It has been proposed that these astrocytes exist in
neuroinflammatory conditions in two differential states of activation
(Liddelow & Barres, 2017). Specifically, proinflammatory A1 astrocytes
damage the synapses and inhibit OPCs, while A2 reactive astrocytes
promote survival of neurons and tissue repair (Liddelow et al., 2017).
In general, astrocytes are cells of the innate immune system that
preserve homeostasis within the CNS. They are considered nontradi-
tional antigen-presenting cells; however, astrocytes are capable of
modulating T cell and microglial immune response within the CNS (Bje-
lobaba et al., 2017; Chastain, Duncan, Rodgers, & Miller, 2011). Astro-
cytes serve to maintain the BBB in normal conditions, but in response
to inflammation they produce cytokines, which allow T cell migration
through the damaged BBB. Previously, it was concluded that astrocytes
become reactive even before infiltration of immune cells in the CNS
(Eng, D’Amelio, & Smith, 1989). At the onset of clinical deficits in EAE
animals, astrocytes start to proliferate, while elongated fibrous
branches border inflammatory infiltrates (Lavrnja et al., 2015). During
the inflammatory phase of the disease, astrocytes undergo massive
proliferation and extensive hypertrophy of cell bodies with enlarged
intertwining processes, forming the scar border (Lavrnja et al., 2012).
Scar formation is a physical border composed of reactive astrocytes
that demark and divide an injured area from the normal-appearing tis-
sue, resulting in extracellular matrix composition changes, which pre-
vent remyelination (Miljkovic, Timotijevic, & Mostarica Stojkovic,
2011). Hypertrophied astrocytes persist in the later stages of the dis-
ease in both white and gray matter of the CNS. The permissive or
inhibitory environment affects the outcome of interaction between
glial cells. Namely, in the inflammatory milieu, astrocytes express che-
mokines that induce migration of OPCs toward the lesion sites; how-
ever, a glial scar can be an obstacle for remyelination (Nair, Frederick, &
Miller, 2008). Further, astrocytes secrete different growth factors,
FGF2 and PDGF among others, which promote OPC proliferation. On
the other hand, these factors can inhibit differentiation of OPCs into
mature oligodendrocytes (Nash, Ioannidou, & Barnett, 2011).
Demyelination is a process that results in damage of oligodendro-
cytes and a loss of myelin. It may occur during EAE in some strains of
susceptible animals and is followed by spontaneous remyelination
(Constantinescu, Farooqi, O’Brien, & Gran, 2011). The exact mechanism
of remyelination is still unknown.
Understanding the multifaceted interaction between astrocytes,
microglia, and oligodendrocytes, which are able to promote direct or
overlapping effects that lead to protective or detrimental pathways in
cells, will broaden our knowledge of demyelination/remyelination in
EAE and ultimately in MS.
5 | SELECTION OF ANIMALS IN EAE
The choice of animals used for the experiments has a profound influ-
ence on disease susceptibility, severity, and course of EAE. The first
choice of animals for studying MS was an EAE model generated in rats.
Indeed, several rat strains, including Lewis, Dark Agouti (DA), and
Brown Norway (BN), show a high reproducibility rate in functional and
histopathological features (Milicevic et al., 2003; Staykova, Paridaen,
Cowden, & Willenborg, 2005; Swanborg, 1995). Below, we give a brief
overview of animal species and strains used for EAE experiments and
specific characteristics of these animal models.
5.1 | Primate model of MS
Considering genetic and immunological resemblance to humans, non-
human primates provide advantageous models of MS. The most
employed nonhuman primates in MS research are common marmosets
and rhesus monkeys.
The first recognized case of EAE in a primate model was seen in the
rhesus monkey (Macaca mulatta), induced by repeated immunization,
although without adjuvant (Rivers & Schwentker, 1935). Three Macaca
species were challenged with MBP or whole-brain homogenate to gener-
ate EAE.M. mulatta is more susceptible thanM. fascicularis, whileMacaca
nemestrina is regarded to be resistant (Wolfe-Coote, 2005). Upon immu-
nization, M. fascicularis usually develops an acute course, although an
MS-like chronic disease pattern can be also found (Kerlero de Rosbo
et al., 2000). The histological feature of this nonhuman primate model is
the presence of inflammation and large demyelinating lesions, leading to
severe damage of white matter, followed by neurodegeneration. Those
changes do not affect the spinal cord (Ravkina, Rogova, & Lazarenko,
1978; Stewart, Alvord, Hruby, Hall, & Paty, 1991). The gray matter
demyelinating lesions are not present in the rhesus EAE model; thus, it is
not suitable for MS research (Burm et al., 2016). Overall, it seems that
white matter lesions in this model are due to inflammatory necrosis
rather than selective demyelination. In this model of EAE, the observed
histological changes bear a resemblance to the acute fulminant forms of
MS rather than the more common chronic forms of MS.
Common marmosets (Callithrix jacchus) are small-bodied Neotropi-
cal primates, easy to maintain in specialized animal husbandries. They
are very fertile and usually give birth to several fraternal siblings per
year. The common marmoset is highly susceptible to EAE. The first
EAE in the marmoset was induced with human myelin emulsified with
CFA and B. pertussis (Massacesi et al., 1995). However, this model has
little similarity with MS because massive inflammation and selective
demyelination occur as in an acute form of neuroinflammation (Kap,
Laman, & ’t Hart, 2010; Maggi et al., 2014).
Active immunization of these marmosets using MBP mixed with
CFA induces a mild form of the disease, while myelin oligodendrocyte
glycoprotein (MOG)-induced EAE produces inflammatory and demyeli-
nating disease with a chronic relapsing–remitting course (Genain &
Hauser, 1997; Uccelli, Giunti, Capello, Roccatagliata, & Mancardi,
2003). It was demonstrated by Jagessar et al. that marmosets can be
sensitized with recombinant human MOG or MOG24–36 in CFA to
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develop EAE, while a severe form of EAE in marmosets can be induced
using MOG34–56 in IFA—that is, without microbial antigens for innate
immune activation (Jagessar et al., 2010). Histopathological examina-
tion of samples from the chronic phase of the disease reveals inflam-
matory demyelinating lesions and widespread astrogliosis and axonal
loss (Mancardi et al., 2001). The area of demyelination varies in size,
number, and location, but with very precise correlation between clinical
and pathological features (Genain & Hauser, 2001; Jagessar et al.,
2012). The marmoset EAE makes a good model for studying MS
because of the resemblance of immune systems (’t Hart et al., 2013),
together with the possibility of exploring T cell–adoptive transfer and
passive transfer of antibodies to genetically distinct siblings (Genain &
Hauser, 2001).
These studies can be done easily because these marmosets are
naturally occurring bone marrow chimeras. This state occurs because
they share a placental bloodstream between fraternal siblings during
pregnancy (Haig, 1999). The natural chimerism provides greater immu-
nological similarity between nonidentical siblings rather than with sib-
lings from other births and induces permanent tolerance (Hamawy &
Knechtle, 1998). This makes fraternal siblings equally allotolerant,
allowing adoptive transfer toward a fraternal sibling’s alloantigen in
each marmoset (Haig, 1999). This leads to functional immune tolerance,
making it possible to perform T cell transfer studies between fraternal
siblings of a twin because they are immunologically compatible (Mans-
field, 2003). Both rhesus monkey and common marmosets are equally
prone to EAE induction; however, these models require different adju-
vants for EAE induction with divergent disease progression (Maggi
et al., 2014). Although rhesus monkeys are evolutionary closer to the
humans than marmosets, rhesus monkeys display only acute EAE
(Kerlero de Rosbo et al., 2000), while marmosets develop relapsing-
remmiting form of EAE (’t Hart et al., 2013).
5.2 | Rats in EAE
The Lewis inbred rat strain has been used for EAE studies since the
1960s (Swanborg, 1995). This strain is exquisitely susceptible to EAE,
induced by guinea pig myelin antigens (Swanborg, 2001), which have
been shown to be potent encephalitogens compared with rat myelin
antigens (Gould, Stepaniak, & Swanborg, 1994). In general, among dif-
ferent autoantigens, myelin proteins such as MBP and MOG have
proved to be stronger encephalitogenic epitopes than proteolipid pro-
tein (PLP), which fails to induce EAE in Lewis rats (Stepaniak, Wolf,
Sun, & Swanborg, 1997). In addition, MBP obtained from human, rab-
bit, or bovine subjects have shown to be inadequate for EAE induction
(Mannie, Swanborg, & Stepaniak, 2009). There is ample evidence that
after immunization with CNS antigens mixed with CFA, Lewis rats
develop an acute monophasic form of the disease (Shin, Ahn, & Matsu-
moto, 2012). In this strain, after spontaneous recovery, EAE cannot be
induced again (Willenborg, 1981). Because this strain is syngeneic, pas-
sive EAE can be induced to define a role of T cells (Gould et al., 1994).
Further, there are no sex differences in inducing a disease.
Pioneering work by Levine and Wenk, using guinea pig MBP mixed
with CFA, additionally injected with pertussis toxin, induced hyperacute
EAE characterized by massive inflammation that correlated with clinical
signs (Levine & Wenk, 1964, 1965). Later, pertussis toxin was excluded
from adjuvants used to afflict animals. The rat or guinea pig MBP/CFA-
induced EAE develops as an acute widespread encephalomyelitis, mani-
fested bymassive inflammation and the presence of a few demyelination
foci, especially at the dorsal root entry zone (Pender, Tabi, Nguyen, &
McComb, 1995; Shin et al., 2012). However, it has been argued that the
observed demyelination is probably due to perivascular cuffing leading
to edema, rather than an actual loss of myelin (Batoulis, Addicks, &
Kuerten, 2010). Although demyelination is not a prominent feature after
active induction with myelin antigens, it was reported that induction
with rat MOG (aa1–125) leads to severe loss of myelin, together with
axonal damage (Adelmann et al., 1995). On the contrary, sensitization
with rat MOG in different doses of IFA fails to induce EAE in Lewis rats;
however, when additionally injected with proinflammatory cytokines
(Kerschensteiner et al., 2004) or growth factor, such as VEGF (Sasaki,
Lankford, Brown, Ruddle, & Kocsis, 2010), rats displayed a highly repro-
ducible inflammatory demyelination, even in gray matter, where cortical
EAE lesions were observed (Merkler, Ernsting, Kerschensteiner, Bruck, &
Stadelmann, 2006; Storch et al., 2006). Further, PLP/CFA induces inflam-
matory demyelination, predominately in the spinal cord, while demyelin-
ation at dorsal root entry is absent (Chalk, McCombe, Smith, & Pender,
1994). Severe demyelination with inflammation throughout the CNS,
with minimal functional outcomes, was seen in passive EAE, with adop-
tive transfer of S100b-specific T cells (Kojima et al., 1994). Also, chronic–
relapsing EAE can be induced in Lewis rats using guinea pig spinal cord
homogenate and additional treatment with cyclosporine A (Tanuma,
Shin, Kogure, & Matsumoto, 1999). A detailed overview of inducing EAE
in Lewis rats has been extensively reviewed elsewhere (Pitarokoili,
Ambrosius, & Gold, 2017).
Another highly EAE susceptible strain is the DA rat. DA rats have
distinctive immunological and genetic features, including elevated basal
levels of IL-2 (Vukmanovic, Mostarica Stojkovic, & Lukic, 1989), IFN-g
(Arsov et al., 1995), and TNF-a (Lukic, Stosic-Grujicic, & Shahin, 1998),
making them prone to various autoimmune-mediated diseases, includ-
ing adjuvant arthritis (Cannon, Woods, Clayton, & Griffiths, 1993) and
multiple low-dose streptozotocin-induced diabetes mellitus (Stosic-
Grujicic et al., 2001).
As observed in Lewis rats, DA rats generate acute monophasic EAE
when afflicted with MBP or MBP peptides emulsified in CFA. However,
there is a difference in the encephalitogenic potential of MBP epitopes
between these two strains. Namely, a severe form of EAE developed
upon immunization with MBP63–81 in DA rats, while the disease was
completely absent in Lewis rats. In addition, MBP87–99 failed to induce
disease in DA rats but generated acute monophasic disease in Lewis
rats (Stepaniak et al., 1997). Acute monophasic disease can be induced
using whole spinal cord homogenate combined with CFA (Lavrnja et al.,
2008, 2012), where the severity of disease is dependent on the amount
of additionally administered M. tuberculosis (Milicevic et al., 2003). It
was also reported that in DA rats, the homologous, rather than heterol-
ogous, tissue is a more efficient encephalitogen (Stosic-Grujicic, Ramic,
Bumbasirevic, Harhaji, & Mostarica-Stojkovic, 2004). Furthermore, DA
rats can develop disease by using a single injection of spinal cord tissue,
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without any adjuvant. In addition, upon recovery from clinical symp-
toms, EAE disease can be reinduced by immunization using spinal cord
tissue and CFA (Stosic-Grujicic et al., 2004).
The differences in the onset and progression of disease are
observed between male and female DA rats. Recently, it was reported
that male rats develop a more severe disease, although they display
lower disease incidence compared with female rats (Nacka-Aleksic
et al., 2015). Also, the mortality rate was higher in male (Stojkov et al.,
2008) than in female DA rats (Lavrnja et al., 2009) after immunization
with whole spinal cord emulsified with CFA. Furthermore, females
develop neuromyelitis optica, while demyelination of the optic nerve
does not occur in male DA rats (Storch et al., 1998b).
DA rats afflicted with syngeneic spinal cord with IFA developed a
chronic–relapsing EAE model (Lorentzen et al., 1995). Similarly, relaps-
ing–remitting EAE can be induced with MOG(aa1–125) mixed with CFA
(Weissert et al., 1998, 2001). Adoptive transfer experiments in DA rats
served to elucidate a basic role of T cells and antibody-mediated demye-
lination. DA rats induce a severe form of EAE in adoptive transfer experi-
ments with MOG-specific T cells, while Lewis rats develop mild disease
with massive inflammation (Kojima et al., 1994; Storch et al., 1998a). The
progression of EAE in these models is controlled by T cell activity. Histo-
logical observation proposed that this model is characterized by inflam-
mation rather than demyelination (for details, see Figure 2).
In general, regardless of the antigen used for immunization, DA rats
display perivascular and subpial inflammation, mediated by T cells and
macrophage/microglia (Lavrnja et al., 2009; Milicevic et al., 2003; Storch
et al., 1998b; Trifunovic et al., 2015). Those events are associated with
the demyelination process, together with neurodegeneration, mainly
seen in the lumbosacral region of the spinal cord (Lavrnja et al., 2012;
Milicevic et al., 2003; Papadopoulos, Pham-Dinh, & Reynolds, 2006).
Around areas of demyelination, reactive astrocytes forming glial scar can
be found (Lavrnja et al., 2012, 2015). In addition, there is an accumulation
of T cells and neutrophils in cerebrospinal fluid, suggesting that in EAE,
choroid plexus is a site of entrance for immune cells (Schmitt et al.,
2012). Recently, immunization using MOG/IFA with additionally adminis-
tered cytokines led to the development of widespread cortical demyelin-
ation in both hemispheres (Gardner et al., 2013; Ucal et al., 2017).
The spontaneous recovery from disease in Lewis and DA rats
probably occurs because of activation-induced cell death in the target
tissue (Lukic, Mensah-Brown, Galadari, & Shahin, 2001). It appears that
remission occurs through elimination of proinflammatory cells. The
other factors that contribute to the recovery of the disease include
activation of Tregs, which produce anti-inflammatory mediators and
consequently defeat encephalitogenic T cells (Castelo-Branco et al.,
2014; Constantinescu et al., 2011). Further, differentiation of M1 mac-
rophages (found to be predominantly present at the onset of the dis-
ease) into M2 macrophages has a neuroprotective effect (Shin et al.,
2012). Although it has been reported that natural killer cells can
increase or decrease the severity of the disease, a recent report points
to the regulatory role of these cells leading to remission of EAE and
MS (Chanvillard, Jacolik, Infante-Duarte, & Nayak, 2013).
The BN rat has been traditionally considered an EAE-resistant
strain because of the lack of the disease upon immunization with
guinea pig CNS homogenate combined with CFA. The observed resist-
ance is linked to its specific genetic background, related to both Major
histocompatibility complex (MHC) and non-MHC regions of the
genome (Levine & Sowinski, 1975). However, the innate immune
response to myelin antigens with carbonyl iron results in EAE develop-
ment (Levine & Sowinski, 1975; Staykova, Linares, Fordham, Paridaen,
& Willenborg, 2008). Similarly, BN rats are susceptible to antibody-
mediated diseases, where MOG/CFA-induced immunization results in
massive inflammation and demyelination in the spinal cord (Meyer
et al., 2001; Stefferl, Linington, Holsboer, & Reul, 1999), as well as an
extensive demyelination of the optic nerve (Fairless et al., 2012). These
studies suggest that the haplotype controls MOG-induced immune
response and point to the B cell–mediated autoantibody response as
an important player in the degree of susceptibility to develop a disease
(Stefferl, Brehm, et al., 1999). Besides the obvious involvement of Th2-
type immune response in proneness to EAE, a number of non–MHC-
regulated mechanisms have been proposed as factors contributing to
the development of EAE. In general, robust HPA axis response (Stefferl,
Linington, et al., 1999), endogenous corticosterone level (Peers, Dun-
can, Flower, & Bolton, 1995), increased TGF-b production (Fournie
et al., 2001), and a defect in the CD8 cell compartment (Cautain et al.,
2001) modulate the susceptibility to EAE in BN rats. Overall, this strain
is suitable to investigate Devic’s disease after MOG/CFA immunization
(Gold et al., 2006).
5.3 | Mice in EAE
Although immunization of susceptible rats does not need pertussis for
amplification of the immune response, mice are used more often in
EAE experiments. Mice are cheaper to maintain and are easily geneti-
cally manipulated (Miller & Karpus, 2007); transgenic and gene knock-
out models are widely used (Croxford et al., 2011).
For active EAE disease development, mice need to be induced
with CFA and pertussis toxin. Mice differ in susceptibility to specific
antigens. Specifically, the SJL strain of mice is susceptible to PLP,
MOG, and MBP immunization and often exhibits a relapsing–remitting
form of the disease (Kono et al., 1988; Miller & Karpus, 2007). There-
fore, this strain is useful in studying T cell–mediated demyelination,
together with evaluation of resident macrophage-driven damage that
controls the later stages of chronic disease. Immunization of SJL mice
with MBP or its peptide induces a relapsing form of the disease but
requires administration of pertussis toxin at the time of immunization,
and again 48hr later (Miller, Karpus, & Davidson, 2007; Zamvil et al.,
1985). Young male SJL mice immunized with PLP are relatively resist-
ant to EAE, whereas older male and female SJL mice are more suscepti-
ble and develop demyelination lesions (Rasmussen et al., 2007). MOG
is expressed at relatively low levels on the surface of myelin sheaths;
however, it proves to be encephalitogenic in C57BL/6 mice (Delarasse,
Smith, Baker, & Amor, 2013). Young C57BL/6 mice develop an acute
monophasic form of EAE, whereas middle-aged males developed
severe chronic EAE (Ditamo, Degano, Maccio, Pistoresi-Palencia, &
Roth, 2005; Matejuk, Hopke, Vandenbark, Hurn, & Offner, 2005).
Administration of pertussis is required for disease induction with
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MOG35–55/CFA in C57BL/6 mice, which develop a self-limited mono-
phasic disease (Bittner, Afzali, Wiendl, & Meuth, 2014; Schreiner,
Heppner, & Becher, 2009). Similarly, PL/J mice develop an acute mono-
phasic disease course (Schreiner et al., 2009; Terry, Ifergan, & Miller,
2016). Alternatively, the C57BL/6 strain of mice is often induced with
MOG peptide plus adjuvant to develop a chronic form of EAE (Bernard
et al., 1997). In addition, the pathogenic B cell epitope of MOG113–127
induces EAE, suggesting that this strain may be useful for immunologi-
cal studies (Delarasse et al., 2013). Previously, it was reported that
C57BL/6 mice immunized with MOG35–55 develops cortical and cal-
losal lesions (Mangiardi et al., 2011). However, in MOG35–55- or
rMOG1–125-immunized C57BL/6 mice, cortical demyelination lesions
are not a regular feature of EAE (Lagumersindez-Denis et al., 2017). In
general, EAE induction in C57BL/6 mice displays heterogeneity in dis-
ease induction and progression. Namely, the ongoing disease is
dependent on the amount of M. tuberculosis in the CFA (Terry et al.,
2016) and pertussis toxin as well (Croxford et al., 2011). Thus, the
more reliable and reproducible mouse model for EAE induction is in
SJL/J mice (Terry et al., 2016), where the disease can be induced with
some myelin antigens (PLP) without pertussis toxin (Miller et al., 2007).
Passive EAE can also be induced in SJL or C57BL/6 mice. It is
accomplished by an adoptive transfer of myelin-activated lymphocytes
from mice immunized with these encephalitogenic myelin antigens.
Although EAE induced by adoptive transfer results in a severe form of
the disease, the clinical and histological findings in passive EAE resemble
those seen after active EAE. However, T cells from SJL/J mice are more
encephalitogenic than from C57BL/6. In this manner, only by using a
large number of activated and Th1-polarized MOG-specific T cells can
passive EAE be induced in C57BL/6 mice (Croxford et al., 2011).
5.4 | Mouse model of chronic EAE
Guido Biozzi reported a mouse strain that developed high titers of
antibodies when exposed to specific antigens. Therefore, this animal
strain was found to be suitable for inducing EAE. Indeed, the Biozzi
ABH strain was highly susceptible to development of EAE. Following
immunization with myelin antigens, Biozzi ABH mice generate
relapsing–remitting EAE, which, in later stages, results in a steady
progression of the disease and may be used for studying both
relapsing–remitting and secondary progressive MS (Al-Izki, Pryce,
Jackson, Giovannoni, & Baker, 2011; Hampton et al., 2008). Biozzi
ABH mice exert a robust antibody response and widespread demyelin-
ation in response to antigens, making this strain a good model for MS
research (Al-Izki et al., 2012).
A variety of myelin epitopes have been shown to be encephalito-
genic in this mouse strain (Amor, Smith, Hart, & Baker, 2005). In this
disease, there is a lack of protective autoimmunity because this strain
is unaffected by innate lymphoid cell involvement (Al-Izki et al., 2011).
Age is a limiting factor in EAE development—it appears that young
mice are resistant, while aged mice are more susceptible to EAE induc-
tion (Peferoen et al., 2016). This can be explained by the age-related
decline in antigen-presenting cell function and the presence of
myeloid-derived suppressor cells in older mice. Biozzi ABH mice display
the pathological hallmarks of MS, such as inflammatory-mediated
demyelination, together with neurodegeneration (Hampton et al.,
2008; Jackson, Lee, Nikodemova, Fabry, & Duncan, 2009; Peferoen
et al., 2016). During relapses, these mice undergo excessive demyelin-
ation, where demyelination areas are filled with T cells, macrophages,
and immunoglobulin depositions (Amor et al., 2005; Baker et al., 1990;
Kipp et al., 2017). It is interesting that autoimmune tolerance can elimi-
nate relapses, but permanent neurological deficits are accumulated
slowly (Pryce et al., 2005). Areas of demyelination contain OPCs
(Hampton et al., 2008), and it has been suggested that early tolerance
is also associated with increased remyelination (Hampton et al., 2013).
The pitfall of this model is that the observed chronic disease is not clin-
ically progressive, although there is an accumulation of neurological
deficits over time. Clinical neurological disease, accompanied by axonal
loss and demyelination of gray matter, can also be induced in Biozzi
ABH mice immunized with neurofilament-L and CFA (Huizinga et al.,
2007a; Puentes et al., 2013). It appears that this disease is mediated by
CD41 T cells directed against neurofilament-L and that it fails to repro-
duce the chronic phase of disease. Overall, it seems that neurodegener-
ation occurs as a consequence of direct interaction between
autoreactive T cells and neurons (Huizinga et al., 2007b; Peferoen
et al., 2016; Puentes et al., 2013).
Understanding the strain differences in cellular and molecular
mechanisms in this experimental autoimmune model will provide a bet-
ter insight for the complex clinical, immunological, and genetic diversity
associated with MS.
5.5 | Genotypic characteristics of animals used
in EAE research and EAE phenotype
Genetic predisposition to MS is traditionally associated with major his-
tocompatibility complex or human leukocyte antigen (MHC and HLA,
respectively) locus on chromosome 6. Some class II HLA alleles (e.g.,
HLA-DRB1*15: 01, HLA-DRB1*13: 03, HLA-DRB1*03: 01, HLA-
DRB1*08: 01, HLA-DQB1*03: 02) are considered to carry significant
risk, whereas some class I alleles (e.g., HLA-A*02: 01, HLA-B*44: 02,
HLA-B*38: 01, HLAB*55: 01) are considered protective (de Jong et al.,
2002; Marrosu et al., 2001; Moutsianas et al., 2015; Silva et al., 2007).
Genome-wide associated studies also have implicated over 100 differ-
ent, non-MHC genes in MS susceptibility (De Jager et al., 2009; Hafler
et al., 2007).
The same concept is true regarding susceptibility of different
strains of rats and mice to EAE. The identification of loci involved in
autoimmunity in laboratory animals was done by comparing inbred
strains susceptible to EAE and strains in which EAE could not be
induced, with congenic strains of animals. Both genetic and epigenetic
interactions were shown to contribute to the EAE phenotype in mice
(Sobel, 2000; Sobel, Tuohy, & Lees, 1991).
Backcrossing studies in rats also revealed that both MHC and non-
MHC genes determine the susceptibility to EAE (Lorentzen et al.,
1997). Further, the DA MHC haplotype (RT1.av1) was associated with
relapses and prolonged inflammatory response, while non-MHC DA
genes intensify inflammation. Congenic strains of the susceptible DA
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strain and resistant Piebald Virol Glaxo strain or ACI strain (which all
share MHC RT1.av1 haplotype) enabled identification of various non-
MHC loci involved in EAE susceptibility. Multiple loci on chromosomes
10, 12, 13, and 18 were the first to be identified (Dahlman et al., 1999).
It was later established that the locus termed Eae19 on chromosome
15 (Sheng et al., 2005); Eae20, Eae21, and Eae22 on chromosome 4
(Jagodic et al., 2005); as well as Eae23 on chromosome 17 and Eae24-
Eae27 on chromosome 4 (Marta et al., 2010) all contribute to specific
features of the disease. For example, the Eae23 locus contains the
Zeb1 gene, which is a known repressor of IL-2, while anti-MOG anti-
body levels for IgG1 and IgG2b are linked to Eae24 and Eae26. The
same group also established that parent-of-origin effects, which play a
role in MS (Ruhrmann, Stridh, Kular, & Jagodic, 2015), also influence
EAE (Jagodic et al., 2005; Stridh et al., 2014). Surprisingly, it was estab-
lished that a substantial percentage of disease-predisposing loci (up to
54%) depend on parental transmission. Backcrossing experiments also
confirmed that imprinting of the Y chromosome of the susceptible
strain contributes to disease proneness, while paternal imprinting of an
atypical notch ligand, Dlk1 on chromosome 6, adds to disease severity
(Stridh et al., 2014). Epigenetic factors, often referred to as missing her-
itability, were (almost two decades ago) proposed to influence EAE
occurrence, severity, neurological score, and CNS lesion distribution in
mice (Sobel, 2000). The specific genes involved in epistatic interactions
that regulate the EAE phenotype are just beginning to emerge.
6 | NEXT-GENERATION ANIMAL
MODELS OF MS
While EAE is often disputed as a true model for MS, it is, up to now, the
only model that can reproduce at least some aspects of this human dis-
ease. It is thus not surprising that all novel models are actually using EAE
as a foundation. With the expansion of genetic modifications in rodents,
it became possible to generate various transgene animals that are used
to evaluate the contribution of specific genes to the development and
resolution of EAE. Various knockout and, with the development of Cre-
lox technology, conditional knockout mice have been used in EAE
research. Because C57BL/6J mice are the preferred background for
genetic manipulations, this promoted the development of the EAE model
in this strain. Listing even some of the gene deletions employed in the
EAE model would be exhaustive and beyond the scope of this review. In
this section, we will give an overview of other genetic manipulations that
have been developed to improve EAE as a disease model for MS.
6.1 | Genetic manipulations in spontaneous
EAE models
In 1993, Goverman et al. first reported that manipulation of the MBP-
specific T cell receptor in B10.PL mice of H-2u haplotype resulted in
spontaneous EAE, albeit only in animals that were not housed in sterile
conditions. The onset of disease occurred at different ages, and the
actual frequency of spontaneous illness was probably below 50%. In
transgenic animals housed in both sterile and nonsterile conditions,
administration of pertussis toxin alone could induce a disease similar to
EAE induced in nontransgenic animals subjected to immunization with
MBP and pertussis toxin emulsion (Goverman et al., 1993). Another
research group crossed animals with MBP-T cell–specific receptor with
RAG-1–deficient mice to obtain a line of mice that expressed modified
TCR in CD4 cells only. These animals developed EAE within 12 months
(Lafaille, Nagashima, Katsuki, & Tonegawa, 1994). Later, SJL/J mice
with PLP-specific TCR also displayed inflammatory foci in the CNS and
EAE (Waldner, Whitters, Sobel, Collins, & Kuchroo, 2000), while MOG-
specific TCR resulted in spontaneous optic neuritis in 30% of C57BL/6
mice; EAE develops in 4% to 15% of animals (Bettelli et al., 2003).
These mice were termed 2D2 and they are the most frequently used
model of spontaneous EAE.
Although CD8T cells have a distinct role in MS pathology, intro-
duction of MBP-specific receptors in mouse CD8 TCR did not result in
spontaneous disease (Perchellet, Stromnes, Pang, & Goverman, 2004);
however, a viral infection could trigger autoimmunity via activation of
CD8 cells that express receptors for both viral antigens and MBP (Ji,
Perchellet, & Goverman, 2010). In pursuit of a better model that would
represent CD8T cell involvement in CNS autoimmunity, CD8 TCR was
made specific for ovalbumin, while ovalbumin itself served as a self-
antigen, expressed under the MBP promoter in oligodendrocytes. In
these animals, spontaneous and severe EAE was observed early, from
12 to 19 days of life (Na et al., 2008). Similarly, Saxena et al. expressed
influenza hemagglutinin in oligodendrocytes; although these animals
did not show spontaneous illness, the transfer of preactivated
hemagglutinin-specific CD8T cells could elicit EAE (Saxena et al.,
2008). More recently, CD8 TCR was modified for GFAP reactivity,
which led to spontaneous relapsing–remitting EAE (Sasaki et al., 2014).
Increasing interest in B cells for CNS autoimmunity led to a gener-
ation of transgenic mice with manipulated B cell receptors (BCRs). Dou-
ble transgenics carrying MOG-specific CD4T cells (2D2) and a heavy
chain of MOG-binding immunoglobulin were the first models that
aimed to evaluate the involvement of B cells in spontaneous EAE (Bet-
telli, Baeten, Jager, Sobel, & Kuchroo, 2006; Krishnamoorthy, Lass-
mann, Wekerle, & Holz, 2006). Both groups concluded that the
interaction between T and B cells drives their own activation.
Transgenic mice that carry human genes involved in antigen proc-
essing and presentation were constructed to serve as tools for validat-
ing the encephalitogenic potential of human T cells. The first transgenic
mouse model expressing human MBP 84–102 TCR and HLA DR15
was described by Madsen et al. (1999). In 4% of these animals, sponta-
neous EAE occurred; however, in a RAG-2–deficient background, all of
the mice eventually showed the symptoms of spontaneous disease.
Later, a human PLP 45–53 CD8 TCR mouse was developed. A double
transgene carrying PLP45–53 TCR and a human HLA-A3 showed spon-
taneous MS-like disease. Further, the presence of HLA-A2 suppressed
the disease (Friese et al., 2008), thus supporting the findings of a study
that found an increased presence of HLA-A3 in MS patients, and sug-
gested a protective role for HLA-A2 (Fogdell-Hahn, Ligers, Gronning,
Hillert, & Olerup, 2000).
The development of new humanized models could include other
proteins involved in MS pathogenesis; however, introducing multiple
genes is technically demanding and increases the model’s complexity.
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6.2 | Manipulation of sex chromosomes
in EAE research
Given the pronounced sex bias of MS, a necessity to compare males
and females in EAE emerged. However, it is suspected that gonadal
steroids are not the only factor contributing to the female preponder-
ance in MS and other autoimmune disorders. While the use of both
males and females in EAE research (and other research as well) is a
good practice (Clayton & Collins, 2014), another useful model was
developed. Genetic manipulation that moves the Sry gene from the Y
chromosome to the autosome yields mice in which gonadal sex does
not correlate with sex chromosome, thus allowing investigation of sex
chromosome effects without the influence of gonadal steroids. Using
this model, Voskhul’s group was able to show that XX sex complement
contributes to the susceptibility of EAE (Smith-Bouvier et al., 2008). On
the other hand, the same group showed that XY chromosome comple-
ment in SJL mice (either gonadal males or females) displayed a more
severe disease with greater neurodegeneration in the CNS (Du et al.,
2014). These results grant further studies of sex complement influen-
ces on gender differences in MS course and prevalence.
6.3 | Bioluminescence imaging in EAE research
The expression of firefly luciferase under promoters of different genes
enabled monitoring of the processes that involve the target molecule in
living mice. This model was proposed to be a functional and valuable
tool for monitoring whole-body in vivo inflammation in various disease
models including EAE (Hayashi et al., 2015; Li et al., 2008; Yang et al.,
2013). Moreover, bioluminescence imaging was used to track the trans-
planted human embryonic stem cell–derived oligodendrocyte progeni-
tors and neural stem cells during EAE (Ayzenberg et al., 2015; Stefferl,
Brehm, et al., 1999). By expressing firefly luciferase under the IL-6 pro-
moter, Hayashi et al. were able to show bioluminescence in the spinal
cord and brain in the EAE mice (Hayashi et al., 2015). Similarly, mice
with luciferase firefly expressed under a c-Rel promoter showed biolu-
minescence in the spinal cord even before the onset of EAE, indicating
that reporter animals could be a valuable tool for monitoring early
events in EAE development (Yang et al., 2013). In concordance with
this, recording of bioluminescence early after EAE induction in GFAP-
luc animals was suggested to be a predictor of disease severity (Luo,
Ho, Steinman, & Wyss-Coray, 2008).
Although bioluminescence imaging in EAE was recently proposed
to have its shortcomings (Ayzenberg et al., 2015), it may be a valuable
tool in animal model research of MS, especially when validated by
other tools like magnetic resonance imaging and histology (Guglielmetti
et al., 2014).
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